Magnevist(R) and Ultravist(R) are part of Amerinet's Portfolio of
Contracted Contrast Media
WAYNE, N.J., April 8, 2008 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc., a leader in diagnostic imaging, announced today that the company has been awarded a two-year contract by Amerinet, Inc. to make Magnevist(R) (gadopentetate dimeglumine) injection and Ultravist(R) (iopromide) injection available to members of the Amerinet network.
Amerinet is a leading national health care group purchasing organization that serves more than 26,000 acute and non-acute healthcare providers nationwide. Through its Total Spend Management Solutions program, Amerinet strategically partners with health care providers to improve its customers' operating margins by creating efficiencies, reducing costs and identifying new revenue streams. The company is based in St. Louis, with offices in Salt Lake City, Utah, Providence, R.I., and Warrendale, Pa.
"We are pleased to continue our long-standing relationship with Amerinet and remain committed to providing its members with the high-quality, cost-effective products they need to serve their patient community," said Douglas Stefanelli, Vice President and General Manager, Diagnostic Imaging, Bayer HealthCare Pharmaceuticals.
The agreement is effective March 1, 2008 through 2010. It covers Magnevist in multiple presentations, including 5, 10, 15 and 20 mL single-dose vials, 50 and 100 mL pharmacy bulk packages, and 10, 15 and 20 mL pre-filled syringes of Magnevist. Ultravist will be available in four concentrations (150, 240, 300 and 370 mgI) and in a variety of product presentations, including 500 mL pharmacy bulk packages for the 300 mgI and 370 mgI concentrations.
About Magnevist
Magnevist is currently the leading MRI contrast agent in the US and
worldwide, a position attained through a combination of high product
quality and outstanding customer service. Since its int
'/>"/>
| SOURCE Bayer HealthCare Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved |